Menu Search
Equities

Pasithea Therapeutics Corp

KTTA:NAQ

Pasithea Therapeutics Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.31
  • Today's Change-0.33 / -9.07%
  • Shares traded47.48k
  • 1 Year change-55.84%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects Pasithea Therapeutics Corp share price to fall to 2.00 in the next year from the last price of 3.31.
High-39.6%2.00
Med-39.6%2.00
Low-39.6%2.00

Earnings history & estimates in USD

Earnings forecasts are not available for Pasithea Therapeutics Corp. On Aug 15, 2022, Pasithea Therapeutics Corp reported 2nd quarter 2022 losses of -- per share.
Pasithea Therapeutics Corp reported annual 2021 losses of -4.20 per share on Mar 30, 2022.
More ▼

Revenue history & estimates in USD

Revenue forecasts are not available for Pasithea Therapeutics Corp.
Average growth rate-6.67%
Pasithea Therapeutics Corp had revenues for the full year 2021 of 15.00k. Last year the company did not report any revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.